ArticleAge and ageing2025
Glymphatic function associates with Alzheimer's disease-signature region volumes, plasma biomarkers and white matter hyperintensity progression in cognitively unimpaired older adults.
Article in Age and ageing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- DTI-ALPS as a marker of glymphatic function: Review of the literature findings, methodology, and interpretation.Neuroimage. Reports · 2026Article
- Longitudinal Patterns of Brain Parenchymal Damage Associated With the ALPS Index in a Community-Based Cohort.CNS neuroscience & therapeutics · 2026Article
- Serial failure of the brain clearance continuum in Alzheimer's disease: mechanisms and therapeutic perspectives.Journal of neurology · 2026Review
- Sleep-Dependent Clearance of Brain Metabolites via the Glymphatic System: Implications for Alzheimer's Pathophysiology.Brain and behavior · 2026Review
- Association between MRI indicators of the glymphatic system and cognition in high-risk populations for Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Article
- Impairment of Cerebral Interstitial Fluid Dynamics after Whole-Brain Radiotherapy and Its Association with Leukoencephalopathy Development.Yonsei medical journal · 2026Article
- Glymphatic clearance as revealed by diffusion tensor imaging along the perivascular space (DTI-ALPS) is associated with Alzheimer's disease neuropathology and periodic rsEEG alpha rhythms in mild cognitive impairment participants.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundBrain glymphatic system is thought to play a critical role in the pathogenesis of Alzheimer's disease (AD).
objectiveTo investigate the relationships between glymphatic function and AD-signature region volumes, plasma biomarkers and disease progression in cognitively unimpaired older adults.
methodsTwo datasets comprising a total of 229 cognitively unimpaired older adults were enrolled. Brain glymphatic function was assessed using diffusion tensor imaging along the perivascular space (DTI-ALPS). The associations between the DTI-ALPS index and volumes in AD-signature regions, including the basal forebrain, entorhinal cortex and hippocampus, were evaluated, along with white matter hyperintensity (WMH) volumes. In dataset 1 with plasma biomarkers, the mediation effects of DTI-ALPS index on plasma biomarkers and cognition were examined. In dataset 2 with follow-up data, the baseline DTI-ALPS index was correlated with the annual percent change in volumes of AD-signature regions and WMH.
resultsThe DTI-ALPS index showed positive correlations with volumes in the basal forebrain, entorhinal cortex and hippocampus, and negative correlations with WMH volumes in both datasets. The DTI-ALPS index negatively associated with plasma phosphorylated tau (ptau) and mediated the relationship between ptau and cognition. The baseline DTI-ALPS index was negatively associated with WMH progression at follow-up.
conclusionWorse glymphatic system function indicates decreased AD-signature region volumes, severe WMH lesions, elevated plasma ptau, and accelerated WMH progression before the occurrence of objective cognitive impairment. Therapeutic methods targeting the glymphatic system may prevent cognitive decline through the clearance of AD pathological proteins and the deceleration of WMH lesions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.